Trial Profile
Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 13 Mar 2024 Status changed from active, no longer recruiting to completed.
- 18 May 2023 Planned End Date changed from 31 Dec 2022 to 30 Dec 2023.
- 28 Mar 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.